Oncotype DX Breast Cancer Testing
Details
| Contract Title: | Oncotype DX Breast Cancer Testing |
| Published Date: | Mar 4, 2026 |
| Notice Type: | Award (CompetitiveContractAwardNotice) |
| Value Banding: | Low Value |
| Delivery Point: | United Kingdom |
Description:
Oncotype DX is a validated genomic assay recommended by NICE (DG34) for guiding chemotherapy decisions in specific cohorts of early breast cancer. It provides a Recurrence Score that stratifies patients into groups where chemotherapy is beneficial versus where endocrine therapy alone is sufficient....